Pfizer Reports final analysis Data for Sparsentan in Diffuse large B-cell lymphoma

Pfizer today announced final analysis results for Sparsentan in patients with Diffuse large B-cell lymphoma. The study demonstrated that Sparsentan reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Diffuse large B-cell lymphoma and support the continued development of Sparsentan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Sparsentan was consistent with previous observations, with no new safety signals identified.